Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR1D | P28221 | 8/20 | 1.00 |
| ▸ | HTR1B | P28222 | 8/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR7 | P34969 | 5/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 5/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386932 | 1.00 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL6977773 | 0.99 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL13683254 | 0.91 | HTR6 (0.83) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL29496144 | 0.90 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL1136525 | 0.90 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL7199110 | 0.88 | HTR6 (0.82) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL194699 | 0.86 | HTR6 (0.76) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL4801548 | 0.86 | GHSR (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL4801555 | 0.86 | GHSR (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL7197257 | 0.85 | HTR6 (0.77) | HTR6HTR1AHTR1DHTR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1971334-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2007087151-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | WYETH (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | WYETH (US) | 2007-07-19 | — | — | US | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| EP-1301475-B1 | ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY | BIOVITRUM AB (SE) | 2006-11-22 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-1107745-B1 | USE OF 5HT-6 ANTAGONISTS FOR THE TREATMENT OF ADHD | SMITHKLINE BEECHAM PLC (GB) | 2004-10-13 | — | — | EP | claimed |
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | claimed |
| EP-1301475-A1 | ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY | BIOVITRUM AB (SE) | 2003-04-16 | — | — | EP | claimed |
| US-6399617-B1 | ADMINISTERING ARYL SULFONAMIDE COMPOUND FOR PROPHYLAXIS OR THERAPY OF OBESITY | BIOVITRUM AB (SE) | 2002-06-04 | — | — | US | claimed |
| US-20020058655-A1 | NEW USE | BIOVITRUM AB (SE) | 2002-05-16 | — | — | US | claimed |
| WO-2002008179-A1 | ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | claimed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-6399617-B1 | ADMINISTERING ARYL SULFONAMIDE COMPOUND FOR PROPHYLAXIS OR THERAPY OF OBESITY | BIOVITRUM AB (SE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058655-A1 | NEW USE | BIOVITRUM AB (SE) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885HTR1A 5/4885HTR1D 20/4885 |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | ACHE, BCHE, HTR6 | HTR6 3/4885HTR1A 21/4885HTR1D 62/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR6 376/4885HTR1A 156/4885HTR1D 317/4885 |
| US-20020058655-A1 | NEW USE | SULT2A1, SULT1A1, GPR119 | HTR6 1581/4885HTR1A 881/4885HTR1D 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.